Validation of the No Objective Testing Rule and Comparison to the HEART Pathway.. Stopyra JP, Miller CD, Hiestand BC, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Riley RF, Russell GB, Hoekstra JW, Mahler SA. Acad Emerg Med. 2017 Sep; 24(9):1165-1168.
A Prospective Emergency Department Quality Improvement Project to Improve the Treatment of Vaso-Occlusive Crisis in Sickle Cell Disease: Lessons Learned.. Tanabe P, Freiermuth CE, Cline DM, Silva S. Jt Comm J Qual Patient Saf. 2017 Mar; 43(3):116-126.
Use of the HEART Pathway with high sensitivity cardiac troponins: A secondary analysis.. Mahler SA, Stopyra JP, Apple FS, Riley RF, Russell GB, Hiestand BC, Hoekstra JW, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Herrington DM, Burke GL, Miller CD. Clin. Biochem. 2017 May; 50(7-8):401-407.
Cost analysis of the History, ECG, Age, Risk factors, and initial Troponin (HEART) Pathway randomized control trial.. Riley RF, Miller CD, Russell GB, Harper EN, Hiestand BC, Hoekstra JW, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Mahler SA. Am J Emerg Med. 2017 Jan; 35(1):77-81.
Shift in Emergency Department Provider Attitudes Toward Patients With Sickle Cell Disease.. Freiermuth CE, Silva S, Cline DM, Tanabe P. Adv Emerg Nurs J. ; 38(3):199-212.
